You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MEK162

Showing 51 - 68 of 68
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neurofibromatosis Type 1, Plexiform Neurofibroma Trial in United States (Binimetinib)

Active, not recruiting
  • Neurofibromatosis Type 1
  • Plexiform Neurofibroma
  • Birmingham, Alabama
  • +21 more
Dec 4, 2021

Cancer Target Therapy Efficacy

Active, not recruiting
  • Cancer
  • RNA sequencing
  • +5 more
  • Walnut, California
  • +6 more
Sep 13, 2021

Melanoma Trial in Pittsburgh (encorafenib, nivolumab, ipilimumab)

Recruiting
  • Melanoma
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Mar 24, 2022

Biliary Tract Carcinoma, Gallbladder Carcinoma Trial (MEK 162, Gemcitabine, Oxaliplatin)

Withdrawn
  • Biliary Tract Carcinoma
  • Gallbladder Carcinoma
  • MEK 162
  • +2 more
  • (no location specified)
Feb 14, 2018

Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer Trial in Duarte (MEK inhibitor MEK162, leucovorin

Completed
  • Recurrent Colon Cancer
  • +5 more
  • MEK inhibitor MEK162
  • +5 more
  • Duarte, California
    City of Hope Medical Center
Jan 23, 2018

Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma Trial in United States

Recruiting
  • Acral Lentiginous Melanoma
  • +6 more
  • Birmingham, Alabama
  • +309 more
Nov 8, 2021

Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic

Terminated
  • Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
  • +14 more
  • MEK inhibitor MEK162
  • +4 more
  • Stanford, California
    Stanford University, School of Medicine
Dec 4, 2017

Advanced and Selected Solid Tumors, AML, High Risk and Very High Risk MDS Trial in Worldwide (BYL719, MEK162)

Completed
  • Advanced and Selected Solid Tumors
  • +2 more
  • La Jolla, California
  • +15 more
Sep 29, 2017

Advanced Malignant Solid Tumor, Bladder Carcinoma, Breast Carcinoma Trial in Guam, Puerto Rico, United States (drug, procedure,

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +49 more
  • Birmingham, Alabama
  • +1429 more
Aug 17, 2022

Malignant Melanoma Trial in Worldwide (Placebo, Vemurafenib, Cobimetinib)

Completed
Has Results
  • Malignant Melanoma
  • Placebo
  • +2 more
  • Birmingham, Alabama
  • +155 more
Sep 14, 2020

Cancer Trial in Worldwide (Dabrafenib, Trametinib, Panitumumab)

Completed
Has Results
  • Cancer
  • Scottsdale, Arizona
  • +19 more
Sep 30, 2021

Melanoma Trial in Worldwide (LGX818)

Terminated
Has Results
  • Melanoma
  • Nashville, Tennessee
  • +5 more
Nov 10, 2016

Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma Trial in United States (Akt Inhibitor GSK2141795,

Completed
Has Results
  • Estrogen Receptor Negative
  • +6 more
  • Akt Inhibitor GSK2141795
  • +2 more
  • Washington, District of Columbia
  • +7 more
Aug 27, 2019

Rheumatoid Arthritis Trial in Worldwide (ARRY-438162, MEK inhibitor; oral, Placebo; oral)

Completed
Has Results
  • Rheumatoid Arthritis
  • ARRY-438162, MEK inhibitor; oral
  • Placebo; oral
  • Spartanburg, South Carolina
  • +34 more
Nov 15, 2020

Cancer Trial in Japan (Trametinib (single tablet), Trametinib (Multiple tablet))

Completed
Has Results
  • Cancer
  • Trametinib (single tablet)
  • Trametinib (Multiple tablet)
  • Chiba, Japan
  • +4 more
May 3, 2017

Advanced Solid Tumors, Hepatocellular Carcinoma Trial in Merck Serono Co., Ltd for recruiting locations in (Pimasertib)

Terminated
Has Results
  • Advanced Solid Tumors
  • Hepatocellular Carcinoma
  • Merck Serono Co., Ltd for recruiting locations in, Japan
    Please contact
Jul 19, 2017

Pancreatic Adenocarcinoma Trial in Rockland, Darmstadt (Pimasertib, Gemcitabine, Placebo)

Completed
Has Results
  • Pancreatic Adenocarcinoma
  • Rockland, Massachusetts
  • +1 more
Jul 12, 2017

Solid Tumors Trial in United States (Cobimetinib, Pictilisib)

Terminated
Has Results
  • Solid Tumors
  • Baltimore, Maryland
  • +5 more
Nov 4, 2016